

Chinese startups Cure Genetics and Frametact ink \$60 M deal to develop gene therapy for familial neurological diseases

16 September 2023 | News

To accelerate the development of gene therapy products for brain diseases



China-based startup Cure Genetics and Frametact, founded by a molecular neuroscience research team at The Hong Kong University of Science and Technology and Hong Kong Center For Neurodegenerative Diseases, have jointly announced the signing of a collaborative development and licensing agreement.

The partnership will leverage Cure Genetics' proprietary VELP™ platform to develop novel Adeno-Associated Virus (AAV) vectors for the treatment of familial neurological diseases.

According to the agreement, Cure Genetics will receive an upfront and milestone payment totaling \$60 million. Additionally, upon the market launch of the product, Cure Genetics will continue to receive sales royalties based on net revenue.

This collaboration will leverage the extensive expertise of Frametact in the domain of neurological diseases, combined with Cure Genetics' leading technology in AAV vector development and efficient *in vivo* AAV screening. Together, the companies will work on developing treatments for familial neurodegenerative diseases, such as Alzheimer's, Parkinson's, and Huntington's disease.

This collaboration, following a previous partnership with Boehringer Ingelheim, marks another significant step forward for Cure Genetics with a globally leading organisation. It not only validates the global advancement of the VELP™ platform but also signifies a leap forward in Cure Genetics' internationalisation process.